Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages

JF Emile, O Abla, S Fraitag, A Horne… - Blood, The Journal …, 2016 - ashpublications.org
The histiocytoses are rare disorders characterized by the accumulation of macrophage,
dendritic cell, or monocyte-derived cells in various tissues and organs of children and adults …

Macrophage activation syndrome in the era of biologic therapy

AA Grom, AC Horne, F De Benedetti - Nature Reviews Rheumatology, 2016 - nature.com
Macrophage activation syndrome (MAS) refers to acute overwhelming inflammation caused
by a'cytokine storm'. Although increasingly recognized as a life-threatening complication of …

HLH‐2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis

JI Henter, AC Horne, M Aricó, RM Egeler… - Pediatric blood & …, 2007 - Wiley Online Library
In HLH‐94, the first prospective international treatment study for hemophagocytic
lymphohistiocytosis (HLH), diagnosis was based on five criteria (fever, splenomegaly …

Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment

A Ravelli, AA Grom, EM Behrens, RQ Cron - Genes & Immunity, 2012 - nature.com
Macrophage activation syndrome (MAS) is a severe, frequently fatal complication of
systemic juvenile idiopathic arthritis (sJIA) with features of hemophagocytosis leading to …

The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody

R Nakashima, Y Imura, S Kobayashi, N Yukawa… - …, 2010 - academic.oup.com
Objectives. Various autoantibodies are detected in the sera of PM/DM patients. Some of
them are specific to PM/DM patients and closely associated with clinical manifestations of …

Macrophage activation syndrome

A Ravelli - Current opinion in rheumatology, 2002 - journals.lww.com
Macrophage activation syndrome (MAS) is a serious complication of childhood systemic
inflammatory disorders that is thought to be caused by excessive activation and proliferation …

Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised …

K Papp, D Thaçi, D Marcoux, L Weibel, S Philipp… - The Lancet, 2017 - thelancet.com
Background Adalimumab is indicated for the treatment of moderate to severe psoriasis in
adults. We assessed the efficacy and safety of adalimumab in children and adolescents with …

Macrophage activation syndrome: advances towards understanding pathogenesis

AA Grom, ED Mellins - Current opinion in rheumatology, 2010 - journals.lww.com
Macrophage activation syndrome: advances towards understandi... : Current Opinion in
Rheumatology Macrophage activation syndrome: advances towards understanding …

Modern management of children with haemophagocytic lymphohistiocytosis.

GE Janka, EM Schneider - British journal of haematology, 2004 - search.ebscohost.com
Focuses on the management of children with hemophagocytic lymphohistiocytosis (HLH),
an autosomal recessive disease. Conditions leading to HLH; Cardinal symptoms of familial …

High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score

M Bulatović, MW Heijstek, M Verkaaik… - Arthritis & …, 2011 - Wiley Online Library
Objective To design and validate a new questionnaire for identifying patients with
methotrexate (MTX) intolerance, and to determine the prevalence of MTX intolerance in …